These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26881752)

  • 21. Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia.
    Ishii H; Wada M; Furuya Y; Nagano N; Nemeth EF; Fox J
    Bone; 2000 Feb; 26(2):175-82. PubMed ID: 10678413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
    Meng Y; Zhang H; Li Y; Li Q; Zuo L
    Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of 22-oxacalcitriol on secondary hyperparathyroidism in hemodialysis patients.
    Doi S; Yorioka N; Usui K; Shigemoto K; Harada S
    Intern Med; 2003 Oct; 42(10):955-9. PubMed ID: 14606707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bio-intact parathyroid hormone and intact parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism receiving intravenous calcitriol therapy.
    Fujimori A; Sakai M; Yoshiya K; Shin J; Kim JI; Inaba Y; Miyamoto T; Inoue S; Fukagawa M
    Ther Apher Dial; 2004 Dec; 8(6):474-9. PubMed ID: 15663547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD.
    Coyne DW; Goldberg S; Faber M; Ghossein C; Sprague SM
    Clin J Am Soc Nephrol; 2014 Sep; 9(9):1620-6. PubMed ID: 24970869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.
    Wesseling-Perry K; Pereira RC; Sahney S; Gales B; Wang HJ; Elashoff R; Jüppner H; Salusky IB
    Kidney Int; 2011 Jan; 79(1):112-9. PubMed ID: 20861820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PTH secretion in patients with chronic renal failure assessed by a modified CiCa clamp method: effects of 1-year calcitriol therapy.
    Schindler S; Mannstadt M; Urena P; Segre GV; Stein G
    Clin Nephrol; 2004 Apr; 61(4):253-60. PubMed ID: 15125031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A mathematical model of calcium and phosphorus metabolism in two forms of hyperparathyroidism.
    Raposo JF; Pires A; Yokota H; Ferreira HG
    Endocrine; 2012 Apr; 41(2):309-19. PubMed ID: 21874319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calcitriol pulse therapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure. European Study Group on Vitamin D in Children with Renal Failure.
    Ardissino G; Schmitt CP; Testa S; Claris-Appiani A; Mehls O
    Pediatr Nephrol; 2000 Jul; 14(7):664-8. PubMed ID: 10912539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitamin D receptor and analogs.
    Dusso AS; Thadhani R; Slatopolsky E
    Semin Nephrol; 2004 Jan; 24(1):10-6. PubMed ID: 14730505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical effect of intravenous calcitriol administration on secondary hyperparathyroidism. A double-blind study among 4 doses.
    Koshikawa S; Akizawa T; Kurokawa K; Marumo F; Sakai O; Arakawa M; Morii H; Seino Y; Ogata E; Ohashi Y; Akiba T; Tsukamoto Y; Suzuki M
    Nephron; 2002 Apr; 90(4):413-23. PubMed ID: 11961400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium.
    Winer KK; Sinaii N; Reynolds J; Peterson D; Dowdy K; Cutler GB
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2680-8. PubMed ID: 20392870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcitriol resistance in hemodialysis patients with secondary hyperparathyroidism.
    Negri AL; Brandenburg VM
    Int Urol Nephrol; 2014 Jun; 46(6):1145-51. PubMed ID: 24384877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of vitamin D in vascular calcification in chronic kidney disease.
    Wolisi GO; Moe SM
    Semin Dial; 2005; 18(4):307-14. PubMed ID: 16076354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the effects of daily and intermittent-dose calcitriol on serum parathyroid hormone and ionized calcium concentrations in normal cats and cats with chronic renal failure.
    Hostutler RA; DiBartola SP; Chew DJ; Nagode LA; Schenck PA; Rajala-Schultz PJ; Drost WT
    J Vet Intern Med; 2006; 20(6):1307-13. PubMed ID: 17186842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PTH suppression by calcitriol does not predict off-target actions in experimental CKD.
    Svajger BA; Pruss CM; Laverty KJ; Zelt JGE; Jones G; Kaufmann M; Petkovich M; Holden RM; Adams MA
    Pharmacol Res Perspect; 2020 Jun; 8(3):e00605. PubMed ID: 32519465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cortical porosity development and progression is mitigated after etelcalcetide treatment in an animal model of chronic kidney disease.
    Swallow EA; Metzger CE; Newman CL; Chen NX; Moe SM; Allen MR
    Bone; 2022 Apr; 157():116340. PubMed ID: 35085840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease.
    Andress DL; Coyne DW; Kalantar-Zadeh K; Molitch ME; Zangeneh F; Sprague SM
    Endocr Pract; 2008; 14(1):18-27. PubMed ID: 18238737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of calcitriol on serum hepcidin in individuals with chronic kidney disease: a randomized controlled trial.
    Panwar B; McCann D; Olbina G; Westerman M; Gutiérrez OM
    BMC Nephrol; 2018 Feb; 19(1):35. PubMed ID: 29426300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advantages of adjusting the initial dose of intravenous calcitriol according to PTH levels.
    Rodríguez-García M; Fernández-Martín JL; de Castañeda JR; Hervás-Sánchez J; Cannata-Andía JB;
    Kidney Int Suppl; 2003 Jun; (85):S79-82. PubMed ID: 12753272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.